Category Archives: Stem Cells

QTV News: Get Swabbed
Who likes stem cells?From:QueensTVViews:2 0ratingsTime:04:15More inNews Politics

Continue reading here:
QTV News: Get Swabbed - Video

Crystal Castles - INSULIN - official
from the album (III) produced by Ethan Kath lyrics below: "Insulin" (written by Ethan Kath and Alice Glass) We dissolve everything Scratch follicles so they don #39;t grow Expose your shame for all to see Sell your bones as ivory Perfume in my blood Nails grow through the glove Bruise my embryo Lay them down lay them down in rows I sleep for you when you #39;re exhausted Your first born will be accosted Fill their lungs with tar and sage Make the stem cells act their age Perfume in my blood Nails grow through the glove Bruise my embryo Lay them down lay them down in rowsFrom:hologramsViews:1113 70ratingsTime:01:47More inEducation

Go here to see the original:
Crystal Castles - INSULIN - official - Video

MS stem cells trial
Dr Antonio Uccelli from Italy talks about the international MS stem cells clinical trial currently taking place and how it benefits people with MS.From:MSIFmediaViews:2 0ratingsTime:05:47More inNonprofits Activism

Here is the original post:
MS stem cells trial - Video

Laminine Results for Glucoma, Pain a Tumor
These testimonies, all from one family, are Very Poignant and helped them Reclaim their Health! Laminine helps YOU create a Healing Environment in your body by helping the Stem Cells strengthen and rejuvenate your body. To see how Laminine can help you Reclaim YOUR Health visit EggOfLife.com and order yours today.From:RSMalloryViews:0 0ratingsTime:06:05More inScience Technology

Read the rest here:
Laminine Results for Glucoma, Pain

Stem Cells: Revolutionizing the Treatments of Human Diseases
Stem Cells: Revolutionizing the Treatments of Human Diseases, recorded November 7, 2012. Topics Covered: Stem Cells, Developmental Biology, Research For more information and access to courses, lectures, and teaching material, please visit the official UC Irvine OpenCourseWare website at: ocw.uci.eduFrom:UCIrvineOCWViews:2 0ratingsTime:47:25More inEducation

Read more:
Stem Cells: Revolutionizing the Treatments of Human Diseases - Video

cord blood center | Cord Blood Transplant - A Better Alternative to Bone Marrow Transplant
http://www.cordbloodrecommendation.com This is the reason the average price is over $1000. You can also save your baby #39;s life!There are lots of umbilical cord blood banks and/or storage facilities throughout the US. Chemotherapy only kept the cancer under control for 17 months. The likelihood of an Autologous transplant using your own stem cells is 1 in 435 whereas the likelihood of an allogeneic transplant from a matched donor (such as a sibling) is 1 in 400, and the net likelihood of any type of stem cell transplant is 1 in 217. Firstly, the greater immaturity of cord blood stem cells provides a more effective transplant. It is often finished in less than ten minutes by your doctor. e. Furthermore, collecting umbilical cord blood has no controversy since the process does not cause the destruction on the embryos and fetus. Being so, they show greater adaptability to form any cells of the organ where tissue re-growth is needed. According to the informative Web site Should You Bank Cord Blood, regardless of the form of birth, the nurses and doctors in the room will be able to easily collect your child #39;s cord blood. Research which cord blood bank you wish to use carefully and when you have decided give your baby or perhaps someone else the precious gift of life. The collection of this blood is done within 15 minutes after the birth and is not a painful procedure. This is still new methodology but holds great promise for the future of regenerative therapies. Other testing is for ...From:kristinagraddyViews:0 0ratingsTime:01:18More inScience Technology

Continued here:
cord blood center | Cord Blood Transplant - A Better Alternative to Bone Marrow Transplant - Video

Canadian and Italian scientists say they have identified a master control gene for turning on blood stem cells, which could lead to a greatly expanded supply of these precious cells for medical treatments.

The discovery, published Thursday in the journal Cell: Stem Cell, follows another major development in 2011, when the Canadian researchers first isolated a human blood cell in its purest form a single stem cell capable of regenerating the entire blood system.

These advances are critical for people who suffer from blood disorders such as leukemia, a form of cancer. Doctors currently treat leukemia by using chemotherapy to destroy the cancerous cells in the bone marrow, where blood cells are produced, in the process also killing off normal blood cells. The blood system is then replaced with healthy cells from a bone-marrow donor.

Worldwide, about 40,000 people a year receive bone-marrow transplants. But an additional 120,000 patients fail to find a suitable match. Many die on waiting lists.

While blood stem cells taken from an umbilical cord have recently offered an alternative transplant source, they cannot be grown in large enough quantities to treat an adult. And even with last years announcement that Canadians had isolated the prized stem cells that endlessly replenish human blood, they still did not know how to control them.

Stem cells are actually dormant in the cord blood or in your bone marrow. They lie dormant for long periods of time, explained John Dick, a senior scientist at the University Health Networks McEwen Centre for Regenerative Medicine and the Ontario Cancer Institute in Toronto.

But the discovery of a master control gene could mean that scientists will be able to finally harness the power of stem cells. Now we have peered into those cells and identified one of these master regulator switches which actually governs the dormancy, Dick said. By altering the master regulators, you could greatly expand the number of stem cells which could then be used to transplant into an adult.

The researchers still have to identify other genes that regulate blood stem cells. But Dick believes that goal is within their grasp.

See the article here:
Scientists find a master control gene for blood stem cells

By E.J. Mundell HealthDay Reporter

TUESDAY, Nov. 6 (HealthDay News) -- Updated two-year results from a small trial using cardiac stem cells to repair damaged hearts suggest the treatment's healing effect persists.

Patients with heart failure caused by prior heart attacks who got the treatment continue to see reductions in cardiac scar tissue, improvements in the heart's pumping ability and even a boost in their quality of life, researchers said.

These improvements seem to be continuing as time goes on, suggesting that stem cell therapy's healing power hasn't diminished.

"Now we need to perform larger and randomized, blinded studies ... to confirm this data," said study lead author Dr. Roberto Bolli, director of the Institute of Molecular Cardiology at the University of Louisville.

His team presented its results Tuesday at the American Heart Association's annual meeting, in Los Angeles.

According to the AHA, more than 6 million Americans suffer from heart failure, a gradual weakening of the heart often caused by damage from a prior heart attack. Despite its prevalence and lethality, virtually no advance has been made over the past few decades in doctors' ability to treat or reverse heart failure.

That's why the advent of stem cell therapy has encouraged researchers. Stem cells have the ability to turn into myriad living cells, and the hope is that once infused into the heart they can help repair it.

This trial is the first human trial to test this theory using the patient's own cardiac stem cells. The cells used in the trial were harvested from 33 heart failure patients who were undergoing bypass surgery. The cells were then coaxed to multiply into the millions in the lab and then transplanted back into 20 of the patients. The remaining 13 patients did not receive a stem cell infusion and are the "control" group for comparison purposes.

Results gathered one year after treatment showed improvements for the treated patients, but experts questioned whether those gains would fade over time.

See more here:
Two Years On, Stem Cells Still Healing Damaged Hearts

NEW YORK, Nov. 8, 2012 /PRNewswire/ --Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today that a heavily pre-treated patient with a drug-refractory and recurrent blastic plasmacytoid dendritic cell neoplasm (BPDCN) achieved a complete response (CR) following treatment with Stemline's SL-401. BPDCN is a rare and aggressive hematologic cancer which is generally unresponsive to standard treatment regimens. SL-401 is Stemline's lead therapeutic being developed to treat acute myeloid leukemia (AML) and other hematologic cancers.

The patient, a 40-year-old male, developed progressive BPDCN with malignant cells in his blood and bone marrow, which resulted in low blood cell counts despite receiving several intensive high-dose chemotherapy regimens, including bone marrow transplantation. After developing progressively worsening BPDCN following failure of multiple standard drug regimens, his physicians referred him to the MD Anderson Cancer Center in Houston, Texas and the Texas A&M Health Science Center College of Medicine at Scott and White Cancer Research Institute in Temple, Texas, to receive treatment with Stemline's SL-401 in a Phase 1/2 clinical trial. The patient was treated with five daily doses of SL-401, a targeted therapy directed specifically to cells that overexpress the interleukin-3 receptor (IL-3R) on their cell surface. BPDCN is known to overexpress IL-3R. SL-401 has previously been shown to possess potent anti-BPDCN activity in preclinical models. Thirty days after SL-401 treatment, the patient achieved a CR, with no evidence of malignant BPDCN cells in his bone marrow or bloodstream and his blood cell counts; in particular, his absolute neutrophil and platelet counts returned to normal levels. Furthermore, he did not experience any serious side effects from SL-401 treatment. "It is always very gratifying to observe a CR and negligible side effects following use of a new agent in patients with cancers, in which approved treatments are of little to no value," said Dr. Eric Rowinsky, Chief Medical Officer and Head of Research and Development at Stemline Therapeutics. "Since we believe the explanation for this prominent clinical response and lack of side effects is SL-401's specific targeting of IL-3R, which is overexpressed on BPDCN and other hematologic malignancies, Stemline will continue to evaluate and potentially register SL-401 in BPDCN."

BPDCN is a relatively uncommon hematologic cancer of plasmacytoid dendritic cells, which are specialized immune cells that circulate throughout the bloodstream, bone marrow, and many other organs. In BPDCN, the cancer cells typically reside and grow in the skin and bone marrow. Their growth in the bone marrow results in decreased blood cell counts, thereby causing serious infections, bleeding, and invariably death. Although BPDCN can be controlled for brief periods with standard chemotherapy that is used to treat other hematologic cancers, meaningful clinical responses are rare and such treatment often produces serious side effects. There are no therapies approved to treat BPDCN. BPDCN cells express high levels of IL-3R on their cell surface, which served as the rationale for treating the patient with SL-401, which specifically targets the IL-3R. SL-401 has also demonstrated clinical activity in other hematologic malignancies that overexpress IL-3R, including AML and myelodysplastic syndrome (MDS). Other malignancies in which high levels of the IL-3R are expressed include Hodgkin's and non-Hodgkin's lymphoma, chronic myeloid leukemia (CML), and multiple myeloma. Preclinical studies of SL-401 in these cancers have demonstrated favorable anticancer activity. SL-401 is currently being advanced into a registration-directed Phase 2b study in advanced stage AML.

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase 1/2 studies of advanced cancer patients. In a multicenter Phase 1/2 trial in patients with advanced acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), SL-401 demonstrated single agent activity, including durable complete responses (CRs), and an overall survival (OS) improvement relative to historical data in the most heavily pretreated AML patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced AML. In Phase 1/2 trials, Stemline's second clinical stage therapeutic, SL-701, has demonstrated single agent activity including durable CRs and partial responses (PRs) in adult patients with refractory or recurrent glioblastoma and pediatric patients with malignant glioma, as well as an OS benefit in adult patients with refractory or recurrent glioblastoma compared with historical data. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen. For more information, please visit the Company's website at http://www.stemline.com.

Stemline Contact:

Mark Jacobson Director, Corporate Development Stemline Therapeutics, Inc. 750 Lexington Avenue Sixth Floor New York, NY 10022 Tel: 646-502-2307 Email: mjacobson@stemline.com http://www.stemline.com

More here:
Stemline Therapeutics' Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory ...

ScienceDaily (Nov. 8, 2012) Canadian and Italian stem cell researchers have discovered a new "master control gene" for human blood stem cells and found that manipulating its levels could potentially create a way to expand these cells for clinical use.

The findings, published November 8 online ahead of print in Cell Stem Cell, usher in a new paradigm for the regulation of human blood stem cells, says co-principal investigator Dr. John Dick, who holds a Canada Research Chair in Stem Cell Biology and is a Senior Scientist at University Health Network's McEwen Centre for Regenerative Medicine and Ontario Cancer Institute (OCI), the research arm of the Princess Margaret Cancer Centre. He is also a Professor in the Department of Molecular Genetics, University of Toronto.

"For the first time in human blood stem cells, we have established that a new class of non-coding RNA called miRNA represents a new tactic for manipulating these cells, which opens the door to expanding them for therapeutic uses," says Dr. Dick.

In 2011, Dr. Dick isolated a human blood stem cell in its purest form -- as a single stem cell capable of regenerating the entire blood system -- paving the way for clinical uses. He also pioneered the cancer stem cell field by identifying leukemia stem cells in 1994 and colon cancer stem cells in 2007.

OCI lead author Dr. Eric Lechman says the research team removed a master control gene -- microRNA 126 (miR-126) -- that normally governs the expression of hundreds of other genes by keeping them silenced, which in turn keeps the stem cells in a non-dividing dormant state. The method was to introduce excess numbers of miR-126 binding sites into the stem cells by using a specially designed viral vector.

"The virus acted like a sponge and mopped up the specific miRNA in the cells. This enabled the expression of normally repressed genes to become prominent, after which we observed a long-term expansion of the blood stem cells without exhaustion or malignant transformation," says Dr. Lechman.

Adds Dr. Dick: "We've shown that if you remove the miRNA you can expand the stem cells while keeping their identity intact. That's the key to long-term stem cell expansion for use with patients." The co-principal investigator was Dr. Luigi Naldini, Director, of the San Raffaele Telethon Institute for Gene Therapy, Milan.

Dr. Dick's research was funded by the Canadian Institutes of Health Research, the Canadian Cancer Society, the Terry Fox Foundation, Genome Canada through the Ontario Genomics Institute, the Ontario Institute for Cancer Research, the Canada Research Chair Program, the Ontario Ministry of Health and Long-Term Care, the Canada Foundation of Innovation, as well as The Princess Margaret Cancer Foundation.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Go here to see the original:
Stem cell scientists discover potential way to expand cells for use with patients